Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, randomized, control phase III trial, to compare the
efficacy and safety of consolidation therapy with sintilimab (IBI308) versus best supported
care (BSC), in unresectable stage III NSCLC patients who do not experience disease
progression after initial concurrent chemoradiation.